Ignite Creation Date:
2024-05-06 @ 9:26 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02983539
Status:
UNKNOWN
Last Update Posted:
2018-07-02
First Post:
2016-10-27
Brief Title:
Detection of Circulating Tumor Cells in Patients With Sarcomas
Sponsor:
AC Camargo Cancer Center
Organization:
AC Camargo Cancer Center
Study Overview
Official Title:
Detection of Circulating Tumor Cells in Patients With Metastatic Sarcomas
Status:
UNKNOWN
Status Verified Date:
2018-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CTCS
Brief Summary:
The sarcomas represent 1 of all cancers in adults 8 in adolescents and young people and 10 in children Even though it is a rare cancer it contributes to a significant loss of years of life in comparison with other types of cancer due the fact that it affects children and young people The diagnosis and treatment are difficult considering the diversity and rarity of this disease In addition on average more than 50 of patients with high-grade sarcoma present tumor relapse and distant recurrence is considered the main cause of death The presence of Circulating Tumor Cells CTCs in the blood of patients with sarcoma may be an early marker of tumor invasion because it is known that the CTCs circulate in the blood for months or years before the development of metastases The CTCs can be used to monitor the response of the tumor to treatment in order to match time dose and type of therapy
Objectives collect blood from patients with different types of sarcoma leiomyosarcoma synovial sarcoma pleomorphic sarcoma and liposarcoma in order to isolate and quantify CTCs The investigators also have an intention to identify genes of resistance to treatment in these cells
Objectives collect blood from patients with different types of sarcoma leiomyosarcoma synovial sarcoma pleomorphic sarcoma and liposarcoma in order to isolate and quantify CTCs The investigators also have an intention to identify genes of resistance to treatment in these cells
Detailed Description:
Methodology This is a prospective study to be made by whole blood collection from 40 patients with different types of sarcomas leiomyosarcoma pleomorphic sarcoma synovial sarcoma and liposarcoma The collections will be made in three different moments before the beginning of the treatment during and at the end of this 8 mL Blood samples will be processed and filtered on ISET system for the isolation and quantification of CTCs Later it will be performed immunocytochemistry ICQ single andor double staining for protein assessment The following proteins will be assessed CD45 MRP1 MRP2 and MRP7
Expected Results The investigators hope that this study can show if the CTCs can be used as liquid biopsy in patients with leiomyosarcoma synovium and pleomorphic sarcoma and liposarcoma
Expected Results The investigators hope that this study can show if the CTCs can be used as liquid biopsy in patients with leiomyosarcoma synovium and pleomorphic sarcoma and liposarcoma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None